Go Pro

EKF Diagnostics (EKF) Competitors

EKF Diagnostics logo
GBX 26 +0.90 (+3.59%)
As of 11:54 AM Eastern

EKF vs. NIOX, CREO, IUG, NCYT, and IHC

Should you buy EKF Diagnostics stock or one of its competitors? MarketBeat compares EKF Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with EKF Diagnostics include NIOX Group (NIOX), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), and Inspiration Healthcare Group (IHC). These companies are all part of the "medical devices" industry.

How does EKF Diagnostics compare to NIOX Group?

NIOX Group (LON:NIOX) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

NIOX Group has higher earnings, but lower revenue than EKF Diagnostics. NIOX Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NIOX Group£48.70M5.27£995.88M£1.6437.20
EKF Diagnostics£51.56M2.17£4.68M£0.4755.32

NIOX Group has a net margin of 14.37% compared to EKF Diagnostics' net margin of 4.12%. NIOX Group's return on equity of 10.14% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
NIOX Group14.37% 10.14% 3.95%
EKF Diagnostics 4.12%3.01%5.27%

In the previous week, NIOX Group and NIOX Group both had 1 articles in the media. NIOX Group's average media sentiment score of 0.00 equaled EKF Diagnostics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NIOX Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
EKF Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

NIOX Group currently has a consensus target price of GBX 86, suggesting a potential upside of 40.98%. EKF Diagnostics has a consensus target price of GBX 35, suggesting a potential upside of 34.62%. Given NIOX Group's higher probable upside, equities analysts clearly believe NIOX Group is more favorable than EKF Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

7.6% of NIOX Group shares are owned by institutional investors. Comparatively, 22.0% of EKF Diagnostics shares are owned by institutional investors. 5.1% of NIOX Group shares are owned by insiders. Comparatively, 40.0% of EKF Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.513, suggesting that its share price is 49% less volatile than the broader market.

Summary

NIOX Group beats EKF Diagnostics on 7 of the 12 factors compared between the two stocks.

How does EKF Diagnostics compare to Creo Medical Group?

EKF Diagnostics (LON:EKF) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

EKF Diagnostics presently has a consensus target price of GBX 35, indicating a potential upside of 34.62%. Creo Medical Group has a consensus target price of GBX 40, indicating a potential upside of 190.91%. Given Creo Medical Group's higher possible upside, analysts clearly believe Creo Medical Group is more favorable than EKF Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

EKF Diagnostics has a beta of 0.513, indicating that its share price is 49% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.6212822, indicating that its share price is 62% more volatile than the broader market.

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.17£4.68M£0.4755.32
Creo Medical Group£6M11.13-£25.04M£1.0013.75

22.0% of EKF Diagnostics shares are held by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are held by institutional investors. 40.0% of EKF Diagnostics shares are held by insiders. Comparatively, 6.9% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, EKF Diagnostics had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Creo Medical Group. EKF Diagnostics' average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company Overall Sentiment
EKF Diagnostics Neutral
Creo Medical Group Neutral

Creo Medical Group has a net margin of 88.33% compared to EKF Diagnostics' net margin of 4.12%. Creo Medical Group's return on equity of 9.56% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
Creo Medical Group 88.33%9.56%-20.09%

Summary

EKF Diagnostics beats Creo Medical Group on 8 of the 15 factors compared between the two stocks.

How does EKF Diagnostics compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

75.5% of Intelligent Ultrasound Group shares are held by institutional investors. Comparatively, 22.0% of EKF Diagnostics shares are held by institutional investors. 12.8% of Intelligent Ultrasound Group shares are held by insiders. Comparatively, 40.0% of EKF Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Intelligent Ultrasound Group has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.513, indicating that its share price is 49% less volatile than the broader market.

In the previous week, EKF Diagnostics had 1 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Intelligent Ultrasound Group. Intelligent Ultrasound Group's average media sentiment score of 0.00 equaled EKF Diagnostics'average media sentiment score.

Company Overall Sentiment
Intelligent Ultrasound Group Neutral
EKF Diagnostics Neutral

EKF Diagnostics has a consensus target price of GBX 35, indicating a potential upside of 34.62%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe EKF Diagnostics is more favorable than Intelligent Ultrasound Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intelligent Ultrasound Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

EKF Diagnostics has a net margin of 4.12% compared to Intelligent Ultrasound Group's net margin of -23.11%. EKF Diagnostics' return on equity of 3.01% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Ultrasound Group-23.11% -23.58% -13.51%
EKF Diagnostics 4.12%3.01%5.27%

EKF Diagnostics has higher revenue and earnings than Intelligent Ultrasound Group. Intelligent Ultrasound Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A
EKF Diagnostics£51.56M2.17£4.68M£0.4755.32

Summary

EKF Diagnostics beats Intelligent Ultrasound Group on 13 of the 14 factors compared between the two stocks.

How does EKF Diagnostics compare to Novacyt?

EKF Diagnostics (LON:EKF) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

EKF Diagnostics has a beta of 0.513, indicating that its share price is 49% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, indicating that its share price is 11% more volatile than the broader market.

In the previous week, EKF Diagnostics had 1 more articles in the media than Novacyt. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Novacyt. EKF Diagnostics' average media sentiment score of 0.00 equaled Novacyt'saverage media sentiment score.

Company Overall Sentiment
EKF Diagnostics Neutral
Novacyt Neutral

EKF Diagnostics currently has a consensus target price of GBX 35, indicating a potential upside of 34.62%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, research analysts plainly believe EKF Diagnostics is more favorable than Novacyt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Novacyt
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

22.0% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 40.0% of EKF Diagnostics shares are owned by insiders. Comparatively, 0.4% of Novacyt shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

EKF Diagnostics has a net margin of 4.12% compared to Novacyt's net margin of -103.08%. EKF Diagnostics' return on equity of 3.01% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
Novacyt -103.08%-96.44%-27.98%

EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.17£4.68M£0.4755.32
Novacyt£20.03M1.37-£36.80M-£32.00N/A

Summary

EKF Diagnostics beats Novacyt on 14 of the 15 factors compared between the two stocks.

How does EKF Diagnostics compare to Inspiration Healthcare Group?

Inspiration Healthcare Group (LON:IHC) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

EKF Diagnostics has higher revenue and earnings than Inspiration Healthcare Group. Inspiration Healthcare Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspiration Healthcare Group£47.55M0.34-£12.20M-£1.16N/A
EKF Diagnostics£51.56M2.17£4.68M£0.4755.32

EKF Diagnostics has a consensus target price of GBX 35, suggesting a potential upside of 34.62%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe EKF Diagnostics is more favorable than Inspiration Healthcare Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inspiration Healthcare Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

7.4% of Inspiration Healthcare Group shares are owned by institutional investors. Comparatively, 22.0% of EKF Diagnostics shares are owned by institutional investors. 6.1% of Inspiration Healthcare Group shares are owned by company insiders. Comparatively, 40.0% of EKF Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Inspiration Healthcare Group has a beta of 0.872, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.513, suggesting that its stock price is 49% less volatile than the broader market.

In the previous week, Inspiration Healthcare Group had 1 more articles in the media than EKF Diagnostics. MarketBeat recorded 2 mentions for Inspiration Healthcare Group and 1 mentions for EKF Diagnostics. Inspiration Healthcare Group's average media sentiment score of 1.27 beat EKF Diagnostics' score of 0.00 indicating that Inspiration Healthcare Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inspiration Healthcare Group
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
EKF Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

EKF Diagnostics has a net margin of 4.12% compared to Inspiration Healthcare Group's net margin of -2.19%. EKF Diagnostics' return on equity of 3.01% beat Inspiration Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Inspiration Healthcare Group-2.19% -6.49% -3.47%
EKF Diagnostics 4.12%3.01%5.27%

Summary

EKF Diagnostics beats Inspiration Healthcare Group on 13 of the 16 factors compared between the two stocks.

Get EKF Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EKF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EKF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EKF vs. The Competition

MetricEKF DiagnosticsMedical Devices IndustryMedical SectorLON Exchange
Market Cap£111.87M£2.15B£6.80B£2.79B
Dividend Yield4.65%2.64%2.67%6.16%
P/E Ratio55.3215.1427.00368.25
Price / Sales2.17128.46518.6684,392.87
Price / Cash10.6415.9926.6827.89
Price / Book1.694.5610.687.59
Net Income£4.68M£144.75M£3.59B£5.89B
7 Day Performance1.96%-0.98%-0.19%0.05%
1 Month Performance0.39%0.80%1.93%-0.66%
1 Year Performance-0.38%-4.81%25.24%62.48%

EKF Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EKF
EKF Diagnostics
1.7958 of 5 stars
GBX 26
+3.6%
GBX 35
+34.6%
-4.2%£111.87M£51.56M55.32356
NIOX
NIOX Group
1.9629 of 5 stars
GBX 57.36
-0.8%
GBX 86
+49.9%
-17.2%£241.41M£48.70M34.9892
CREO
Creo Medical Group
N/AGBX 14.25
-0.6%
GBX 40
+180.7%
+13.4%£69.23M£6M14.25279
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
NCYT
Novacyt
N/AGBX 35
+1.4%
N/A+4.0%£25.36M£20.03MN/A120

Related Companies and Tools


This page (LON:EKF) was last updated on 7/21/2026 by MarketBeat.com Staff.
From Our Partners